AEON AEON Biopharma, Inc.
Company Analysis
Latest News
AEON Biopharma Amends Warrants, Expects $6.2M in Gross Proceeds from Exercises
AEON Biopharma has amended the terms of its outstanding two-year milestone warrants to lower the exercise price, a move expected to generate approximately $6.2...
AEON Receives FDA Feedback, Clarifying Development Path for BOTOX Biosimilar ABP-450
AEON Biopharma announced it received official minutes from a Type 2b meeting with the U.S. Food and Drug Administration (FDA) regarding the development pathway...
AEON Biopharma reports second quarter 2026 loss while July financing extends runway into 2027
AEON Biopharma reported a net loss of $1.16 million for the second quarter of 2026, primarily reflecting ongoing clinical development costs for its Botox...
AEON Biopharma, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Analysts expect AEON Biopharma to report a Q2 2026 loss of $0.33 per share on zero revenue, reflecting its status as a clinical-stage biotechnology firm. The...
AEON Biopharma Regains Compliance with NYSE American Listing Standards
AEON Biopharma announced it has regained compliance with the NYSE American's continued listing standards as of August 3, 2026. The company resolved previous...
AEON Biopharma Raises Additional $1.5M via Partial Over-Allotment Option Exercise
AEON Biopharma announced it has raised additional capital after underwriters partially exercised their over-allotment option related to the company's public...
AEON Biopharma Closes Public Offering, Raising Approximately $12.2 Million in Net Proceeds
AEON Biopharma has closed an underwritten public offering of common stock, pre-funded warrants, and accompanying milestone warrants, raising net proceeds of...